Stock Price Quote

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal
BSE2336.957.3 (+0.31 %)
PREV CLOSE ( ) 2329.65
OPEN PRICE ( ) 2330.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 976
TODAY'S LOW / HIGH ( )2250.15 2376.05
52 WK LOW / HIGH ( )1762.7 2766.85
NSE2333.955.85 (+0.25 %)
PREV CLOSE( ) 2328.10
OPEN PRICE ( ) 2330.00
BID PRICE (QTY) 2333.95 (52)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8264
TODAY'S LOW / HIGH( ) 2320.00 2373.60
52 WK LOW / HIGH ( )1762.05 2767.1
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995
Management Info
Arvind Lal - Chairman Om Prakash Manchanda - Managing Director
Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-49885050

Email cs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details
Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

01Feb Dr. Lal PathLabs informs about earning
Dr. Lal PathLabs has informed that it attached a copy of Company's Q3 &a..
25Jan Dr. Lal PathLabs informs about closure
Dr. Lal PathLabs has informed that a meeting of the Board of Directors i..
25Jan Dr. Lal PathLabs informs about board m
Dr. Lal PathLabs has informed that a meeting of the Board of Directors i..
25Jan Dr. Lal PathLabs informs about confere
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
17Nov Dr. Lal PathLabs informs about allotme
Dr. Lal PathLabs has informed that the Board of Directors through Circul..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit8832924
Gross Profit 1195 3908
Operating Profit 14525073
Net Sales 476017690

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kovai Medical Center (BSE)
peergroup  3926.20 (2.14%)
M.Cap ( in Cr)4296.15
Apollo Hospital Ent. (BSE)
peergroup  6137.40 (0.90%)
M.Cap ( in Cr)88246.40
Jupiter Life Line (BSE)
peergroup  1355.15 (3.25%)
M.Cap ( in Cr)8885.18
Krishna Inst.Medi (BSE)
peergroup  2247.80 (1.51%)
M.Cap ( in Cr)17988.65
Max Healthcare Inst (BSE)
peergroup  768.00 (4.29%)
M.Cap ( in Cr)74638.73

Shareholding Pattern

PROMOTERS 54.6%
MUTUAL FUNDS/UTI 5.88%
FI/BANKS/INSURANCE 2.73%
NON-INSTITUTION 10.49%
GOVERNMENT 0%
FII 0%

About Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. was incorporated in the year 1995. Its today's share price is 2336.95. Its current market capitalisation stands at Rs 19508.36 Cr. In the latest quarter, company has reported Gross Sales of Rs. 17690.3 Cr and Total Income of Rs.18156.3 Cr. The company's management includes Gurinder Singh Kalra, Vinay Gujral, Rajit Mehta, Arun Duggal, Rohit Bhasin, Somya Satsangi, Sunil Varma, Rahul Sharma, Om Prakash Manchanda, Archana Lal Erdmann, Vandana Lal, Arvind Lal.

It is listed on the BSE with a BSE Code of 539524 , NSE with an NSE Symbol of LALPATHLAB and ISIN of INE600L01024. It's Registered office is at Block E,Sector 18,RohiniNew Delhi-110085, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.